Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls
GUEST
Amanda (Mandy) Mullins, PharmD, BCPS
Clinical Pharmacist Practitioner
Veterans Affairs
Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.
2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.
Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose.
0.05 CEU/0.5 Hr
UAN: 0107-0000-25-371-H01-P
Initial release date: 12/15/2025
Expiration date: 12/15/2026
Additional CPE details can be found here.
